Risk Stratification for Malignant Potential of Intraductal Papillary Mucinous Neoplasms Using the Apolipoprotein-A2...

Area of Science:

• Gastroenterology
• Oncology
• Biomarker Discovery

Background:

• Intraductal papillary mucinous neoplasms (IPMNs) pose a risk of malignancy.
• High-risk stigmata (HRS) and worrisome features (WFs) are key imaging indicators of IPMN malignant potential.
• Accurate stratification of IPMN risk is crucial for patient management.

Purpose of the Study:

• To evaluate apolipoprotein-A2 isoforms (apoA2-i) as a blood biomarker for stratifying the malignant potential of IPMNs.
• To compare the diagnostic performance of apoA2-i with CA19-9 in IPMN risk assessment.

Main Methods:

• Retrospective analysis of 212 patients with IPMNs diagnosed via imaging (MRI, CT, EUS).
• Measurement of apoA2-i and CA19-9 levels in patients and 295 healthy controls.
• Correlation of apoA2-i and CA19-9 levels with imaging-defined IPMN risk categories (HRS, WFs, non-WFs).

Main Results:

• Significantly lower apoA2-i Index levels were observed in IPMN patients with HRS and WFs compared to those without WFs and healthy individuals (P < 0.001).
• CA19-9 levels did not show significant differences across the IPMN risk groups.
• The apoA2-i Index exhibited a higher area under the curve (0.676) than CA19-9 (0.554) in differentiating high-risk IPMNs (P = 0.029).

Conclusions:

• Apolipoprotein-A2 isoforms (apoA2-i) show superior diagnostic performance compared to CA19-9 for detecting IPMNs with malignant potential.
• The apoA2-i Index is a potential biomarker for risk stratification and surveillance of IPMNs.